Delivery Order SPE2DB20D9214-SPE2DB26FD4RH

The Defense Logistics Agency awarded a delivery order valued at $17,746.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, issued on October 30, 2025, with an ultimate completion date of November 21, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying pharmaceutical products to Department of Defense healthcare facilities worldwide.

DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity through the Defense Logistics Agency's Medical Supply Chain division. The company's comprehensive product portfolio includes branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables serving diverse therapeutic categories. Under the PPV-G GEN V contract, designated SPE2DR with a ceiling value of $499,999,999 through December 31, 2036, DMS Pharmaceutical Group is positioned to deliver both routine and specialized pharmaceutical requirements to support Department of Defense military healthcare operations globally, with this delivery order representing one of numerous awards demonstrating consistent performance on federal pharmaceutical supply contracts.